Advances in management of primary myelofibrosis and polycythaemia vera: Implications in clinical practice

Area of Science:

• Hematology
• Oncology
• Internal Medicine

Background:

• Primary myelofibrosis (PMF) and polycythaemia vera (PV) are rare BCR-ABL1-negative myeloproliferative neoplasms.
• These conditions carry risks of thrombosis, bleeding, and disease progression.
• Significant biological and clinical heterogeneity complicates management.

Purpose of the Study:

• To provide an updated overview of diagnosis, prognosis, and treatment for PMF and PV.
• To discuss the translation of evidence-based knowledge into routine clinical practice by a multidisciplinary expert group.

Main Methods:

• Literature review of current evidence on PMF and PV.
• Expert group discussion and consensus building.
• Analysis of clinical practice variations.

Main Results:

• PMF and PV management requires tailored approaches due to disease heterogeneity.
• Updated diagnostic criteria and prognostic factors are crucial.
• Evidence-based treatment strategies are evolving.

Conclusions:

• A multidisciplinary approach is essential for optimal PMF and PV patient care.
• Translating evidence into practice can reduce management variability.
• Continued research is needed to improve outcomes for these rare neoplasms.